相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
Angiotensin blockade therapy and survival in pancreatic cancer: a population study
Scott W. Keith et al.
BMC CANCER (2022)
Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan
Kiyotsugu Iede et al.
PANCREAS (2022)
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
Toshihiko Matsumoto et al.
PANCREAS (2020)
Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study
Samuel J. Tingle et al.
ANTI-CANCER DRUGS (2020)
Multiple Liver Metastases Rather Than the Presence of Liver Metastasis Is a Significantly Poor Prognostic Factor for Patients With Advanced Pancreatic Cancer
Kiyotsugu Iede et al.
PANCREAS (2020)
Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer
Kiyotsugu Iede et al.
CANCER REPORTS (2020)
Predictive implications of decreasedCA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer
Kiyotsugu Iede et al.
CANCER REPORTS (2020)
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer A Phase 2 Clinical Trial
Janet E. Murphy et al.
JAMA ONCOLOGY (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study
Go Ninomiya et al.
INTERNATIONAL JOURNAL OF SURGERY (2017)
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
E. Gabriela Chiorean et al.
BRITISH JOURNAL OF CANCER (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients
Yousuke Nakai et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Helmut Oettle et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2
Yousuke Nakai et al.
INVESTIGATIONAL NEW DRUGS (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1
Yousuke Nakai et al.
CANCER SCIENCE (2012)
How Does Inhibition of the Renin-Angiotensin System Affect the Prognosis of Advanced Gastric Cancer Patients Receiving Platinum-Based Chemotherapy?
Seung Tae Kim et al.
ONCOLOGY (2012)
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
Uwe Pelzer et al.
EUROPEAN JOURNAL OF CANCER (2011)
Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine
Y. Nakai et al.
BRITISH JOURNAL OF CANCER (2010)
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
Carla M. M. Prado et al.
CLINICAL CANCER RESEARCH (2009)
Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy
Stefan Wilop et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
分享论文
